Institutional Ownership
Terns Pharmaceuticals Inc
CUSIP 880881107COM430Q1 2026
13D / 13G Filings
74
Schedule 13D/13G on record
Beneficial Filers
25
Distinct reporting persons
Largest Stake
19.9%
Max % of class reported
Institutional Holders
308
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
74 filings · latest Feb 17, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 17, 2026 | Commodore Capital LP | 13G/A | 11.0% | 1.48M | SEC |
| 2 | Feb 13, 2026 | Vivo Capital Fund Viii, L.P. | 13G/A | 2.5% | 2.70M | SEC |
| 3 | Feb 13, 2026 | Deep Track Capital, LP | 13G/A | 3.0% | 3.15M | SEC |
| 4 | Feb 12, 2026 | Soleus Capital Master Fund, L.P. | 13G/A | 0.2% | 591.1K | SEC |
| 5 | Feb 12, 2026 | Adage Capital Management, L.P. | 13G | 5.1% | 5.55M | SEC |
| 6 | Nov 14, 2025 | Commodore Capital LP | 13G/A | 11.0% | 5.70M | SEC |
| 7 | Nov 5, 2025 | Orbimed Advisors LLC | 13D/A | 4.8% | — | SEC |
| 8 | Oct 31, 2025 | The Vanguard Group | 13G | 5.2% | 4.56M | SEC |
| 9 | Sep 16, 2025 | Commodore Capital LP | 13G | 11.0% | 4.65M | SEC |
| 10 | Aug 14, 2025 | Deep Track Capital, LP | 13G/A | 8.6% | 7.50M | SEC |
64 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Terns Pharmaceuticals Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Blackrock, Inc. | 9.57M | $504.51M |
| 2 | Morgan Stanley | 6.45M | $340.00M |
| 3 | Avoro Capital Advisors LLC | 5.70M | $300.24M |
| 4 | Holocene Advisors, LP | 4.12M | $216.99M |
| 5 | Citadel Advisors LLC | 3.22M | $169.70M |
| 6 | Millennium Management LLC | 3.01M | $158.77M |
| 7 | Hbk Investments L P | 2.95M | $155.52M |
| 8 | Jpmorgan Chase & Co | 2.87M | $151.75M |
| 9 | Balyasny Asset Management L.P. | 2.78M | $146.53M |
| 10 | Franklin Resources Inc | 2.41M | $127.00M |